The purpose of using CRISPR-Cas9 was to investigate the potential therapeutic effect of targeting the BRCA1/TP53/RAS gene, which is commonly mutated in breast and ovarian cancer/cancer [231]. This evidence concerns the gene BRCA1 and ovarian cancer.